Urologix, Inc. (OTCPK:ULGX) will continue reviewing various strategic alternatives available to the Company, including the sale of the Company or its assets, partnering or other collaboration agreements, or a merger, reverse merger or other strategic transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | -.--% |
2016 | A unknown buyer acquired substantially all of the operating assets of Urologix, Inc. | CI |
2015 | Urologix Conducting A Strategic Review | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 2.13K | |
+8.06% | 218B | |
+6.94% | 184B | |
+13.54% | 135B | |
-0.27% | 62.38B | |
+11.59% | 51.37B | |
+7.76% | 50.9B | |
+1.14% | 40.87B | |
+3.21% | 36.28B | |
+26.11% | 31.88B |
- Stock Market
- Equities
- ULGX Stock
- News Urologix, Inc.
- Urologix Conducting A Strategic Review